- Contact Us Now: (202) 589-1834 Tap Here to Call Us
FTC Requires Divestitures to Clear Aurobindo’s Acquisition of Lannett, Reinforcing Longstanding Pharma Merger Policy
On June 18, 2026, the Federal Trade Commission issued a complaint and accepted a proposed consent order requiring Aurobindo Pharma Limited to divest four generic drug products as a condition of completing its approximately $250 million acquisition of Lannett Company, Inc. The action continues the agency’s longstanding approach in pharmaceutical mergers: when a transaction eliminates head-to-head competition between significant suppliers of particular generic drugs, the FTC routinely requires structural divestitures of the overlapping products to an independent, capable buyer. The 2-0 Commission vote and the structure of the remedy reinforce that this policy remains fully intact.
The Transaction and Competitive Concerns
Aurobindo is one of the world’s largest generic pharmaceutical suppliers. Lannett is a long-established U.S. generics manufacturer. The parties compete in multiple product markets. The FTC’s investigation focused on four generic products for which the companies are among only a limited number of independent significant competitors:
- Mycophenolate mofetil oral suspension, an immunosuppressant used to help prevent organ-transplant rejection.
- Niacin extended-release tablets, used to manage cholesterol levels and treat niacin deficiency.
- Pilocarpine tablets, used to treat dry mouth, including after radiation therapy for head and neck cancer or in patients with Sjögren’s syndrome.
- Rabeprazole sodium delayed-release tablets, a proton-pump inhibitor indicated for duodenal ulcers, gastroesophageal reflux disease, and Zollinger-Ellison syndrome.
The complaint alleged that the acquisition would eliminate direct competition between Aurobindo and Lannett in these markets, reducing the number of independent significant competitors. Without a remedy, the deal would increase the likelihood that the combined firm could unilaterally exercise market power and that remaining competitors could engage in coordinated interaction, ultimately forcing customers to pay higher prices for these generic drugs.
The Remedy
Under the proposed consent order, Aurobindo and Lannett must divest all rights and assets related to the four products—including FDA approvals, intellectual property, manufacturing know-how, and related assets—to Quagen Pharmaceuticals LLC, an experienced generic pharmaceutical company. The divestitures must occur no later than ten days after the acquisition closes. The parties are also required to provide transition services so that Quagen can operate the assets effectively from the outset and are subject to a monitor to oversee compliance. An Order to Maintain Assets requires the respondents to continue operating the products in the ordinary course until the divestitures are completed. If Quagen is later found unacceptable, the order provides for an alternative divestiture to a Commission-approved buyer.
Bureau of Competition Director Daniel Guarnera stated that the action protects millions of patients from the threat of higher generic drug prices and reflects the FTC’s commitment to lowering drug costs for Americans.
Continuity of Policy
This outcome is consistent with decades of FTC practice in the generics sector. The agency has repeatedly required divestitures of overlapping products in pharmaceutical mergers precisely because generic markets are often concentrated, price competition is sensitive to the number of suppliers, and barriers to entry (including FDA approval and manufacturing capacity) can be significant. Structural remedies that transfer the overlapping products to a viable independent competitor have been the preferred means of restoring the pre-merger competitive dynamic while allowing the remainder of a transaction to proceed.
The Aurobindo-Lannett consent order follows that template: an early identification of the limited overlaps, negotiation of a structural fix with an experienced upfront buyer, and a 2-0 Commission vote accepting the settlement for public comment. It demonstrates that the current Commission continues to prioritize the preservation of competition in markets for essential generic medicines and remains willing to condition clearance on targeted divestitures when those concerns are substantiated. For parties contemplating generics combinations, the case reaffirms that modest but meaningful product overlaps will still draw scrutiny and that a well-structured, pre-negotiated divestiture package remains the most reliable path to clearance.
Andre Barlow
abarlow@dbmlawgroup.com






